Table 1

Characterization of the low-virulence L. monocytogenes strains
Strains Sub-cutaneous test Phenotypic Groupc Mutations Genotypic Groupd MLST PFGE types
Mean (log spleens) ± S.D.a I/Tb Sequence types ApaI AscI
CHU 860776 e 0 0/5 I PrfA K220T, truncated InlA (76 AA) Ia 13 2 2
CNL 895803 e 0 0/5 I PrfA K220T, truncated InlA (76 AA) Ia 13 2 2
CNL 895804 e 0 0/5 I PrfA K220T, truncated InlA (76 AA) Ia 13 2 2
CNL 895806 e 0 0/5 I PrfA K220T, truncated InlA (76 AA) Ia 13 2 2
CNL 895809 e 0 0/5 I PrfA K220T, truncated InlA (76 AA) Ia 13 2a 2
CNL 895793 e 0 0/5 I PrfA K220T, truncated InlA (76 AA) Ia 13 2a 2
SO49 e 0 0/5 I PrfA K220T, truncated InlA (76 AA) Ia 13 3 23
AF10 e 0 0/5 I PrfA K220T, truncated InlA (76 AA) Ia 13 3 23
99EB24LM 0 0/5 I PrfA K220T, truncated InlA (76 AA) Ia 13 3 23
99EB04LM 0 0/5 I PrfA K220T, truncated InlA (76 AA) Ia 13 3 23
BO18 e 1.31 1/5 I PrfAΔ174-237, truncated InlA (188 AA) Ib 31 77a 61b
BO38 e 0 0/5 I PrfAΔ174-237, truncated InlA (188 AA) Ib 31 77a 61b
AF95 e 0 0/5 I PrfAΔ174-237, truncated InlA (188 AA) Ib 31 77a 61c
99EB15LM 0 0/5 I PrfAΔ174-237, truncated InlA (188 AA) Ib 31 21a 20
NP 26 0 0/5 I PrfA K130Q Ic 2 61a 3
454 e 3.26 ± 0.53 3/20 II mutated PC-PLC (D61E, L183F, Q126K, A223V) 10 9 11
CNL 895807 e 3 1/25 III truncated InlA (25 AA), mutated InlB (A117T, V132I), PI-PLC T262A IIIa 193 1 1
416 e 0 0/5 III truncated InlA (25 AA), mutated InlB (A117T, V132I), PI-PLC T262A IIIa 193 1 1
417 e 2.81 ± 1.47 2/20 III truncated InlA (25 AA), mutated InlB (A117T, V132I), PI-PLC T262A IIIa 193 1 1
BO43 e 2.53 1/5 III truncated InlA (25 AA), mutated InlB (A117T, V132I), PI-PLC T262A IIIa 193 1a 1a
CNL 895795 e 0 0/5 III truncated InlA (25 AA), mutated InlB (A117T, V132I), PI-PLC T262A IIIa 193 1a 1a
DSS794AA1 0 0/5 III truncated InlA (25 AA), mutated InlB (A117T, V132I), PI-PLC T262A IIIa 193 144 33a
DSS1130BFA2 0.47 1/5 III truncated InlA (25 AA), mutated InlB (A117T, V132I), PI-PLC T262A IIIa 193 143 129
DPF234HG2 2.76 ± 0.04 2/5 III truncated InlA (25 AA), mutated InlB (A117T, V132I), PI-PLC T262A IIIa 193 145 33b
AF105 e 0 0/5 III truncated InlA (576 AA) IIIb 9 81 64
442 e 0 0/5 IV 1 6 7
02-99 SLQ 10c Al 2.9 ± 0.05 2/5 IV 1 11 7
3876 3.42 ± 0.2 3/5 IV 1 142 113
3877 2.7 ± 0.2 3/5 IV 1 142 113
N2 3.59 ± 0.48 2/5 IV 10 11 4b
CR282 e 3.01 ± 0.61 2/10 IV 195 158 85
LSEA 99–23 f 4.49 ± 0.89 3/5 IV truncated InlA (576 AA) 9 21a 20
LSEA 99-4f 3.67 ± 0.81 3/5 IV 198 48 101
09-98 SRV 10a Al1 0 0/5 IV 4 37 38b
449 e 0 0/5 V 3 AA deletion at position 742 in InlA 194 8 6
BO34 e 3.63 ± 0.56 5/10 V 2 4a 3
464 e 2.59 ± 0.39 9/15 V 1 9c 4a
09-98 SRV 10b Al2 3.54 ± 0.27 3/5 V 54 135 124
11-99 SRV 1a Al 0 0/5 V 4 37 38b
09-98 HPR 50a Al1 0 0/5 V 3 AA deletion at position 742 in InlA 6 67a 98a
436 e 2.81 ± 0.68 12/20 VI 2 4 3
LSEA 00–14 f 0 0/5 VI 2 106 3a
04-99 EBS 1 lb Al 2.53 ± 1.76 2/5 VI 54 139 125

a Log numbers of Listeria recovered from spleens three days after sub-cutaneous injection into the left hind footpads of immunocompetent Swiss mice with 104 CFU in 50 μL. Values are from infected mice.

b Ratio of infected mice to inoculated mice in sub-cutaneous test.

c These groups are based on combined values of cell invasion, plaque formation, and phospholipase activities.

d These groups are based on sequencing of prfA, plcA, plcB, inlA and inlB genes.

e Results already published in Roche et al. [7].

f Results already published in Kerouanton et al. [10].

Roche et al.

Roche et al. BMC Microbiology 2012 12:304   doi:10.1186/1471-2180-12-304

Open Data